ENANTA PHARMACEUTICALS INC 8-K

What Happened
Enanta Pharmaceuticals, Inc. announced and furnished a press release reporting its financial results for the fiscal quarter ended December 31, 2025. The company filed Form 8-K on February 9, 2026 (Item 2.02) to disclose those quarterly results and included the press release as Exhibit 99.1. The filing is signed by Jay R. Luly, Ph.D., President and Chief Executive Officer.

Key Details

• Form 8-K filed with the SEC on February 9, 2026 (Item 2.02: Results of Operations and Financial Condition).
• The results cover the fiscal quarter ended December 31, 2025.
• Press release reporting the results is furnished as Exhibit 99.1 to the 8-K.
• Filing signed by Jay R. Luly, Ph.D., President and CEO.

Why It Matters
This 8-K tells investors that Enanta has publicly released its latest quarterly results; the attached press release (Exhibit 99.1) is the source for the detailed numbers and management commentary investors need—such as revenue, earnings, cash position and operational updates. Shareholders and prospective investors should review that press release for the specific financial figures and any commentary that could affect near‑term valuation or expectations.